Lung cancer combo trial halted after just 2 patients
NCT ID NCT03436056
First seen Jan 31, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This early-stage trial aimed to test the safety of combining the immunotherapy drug pembrolizumab with targeted radiation (SBRT) in people with advanced non-small-cell lung cancer that had worsened after standard treatments. Only 2 out of a planned 24 patients were enrolled before the study was stopped. The main goal was to check for serious side effects from the combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Marsden NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.